Suppr超能文献

慢性肝病患者的新冠疫苗接种

COVID-19 Vaccines in Patients With Chronic Liver Disease.

作者信息

Sharma Anand, Patnaik Itish, Kumar Ashok, Gupta Rohit

机构信息

Department of Gastroenterology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.

出版信息

J Clin Exp Hepatol. 2021 Nov-Dec;11(6):720-726. doi: 10.1016/j.jceh.2021.06.013. Epub 2021 Jun 19.

Abstract

The COVID-19 pandemic has caused mayhem globally since the beginning of 2020. Owing to the immune dysfunction inherent to cirrhosis and the poor general condition, patients with chronic liver disease (CLD) are at higher risk of mortality and morbidity due to COVID-19. Recently, a number of vaccines against SARS-Cov-2 have been approved for emergency use around the globe. Although the phase 2/3 trials of these vaccines show them to be safe and effective in the general population, data in patients with CLD are scarce. The number of patients with CLD enrolled on these trials is small, and no liver-related adverse effects have been reported yet. Various liver societies have come up with guidelines on vaccination in this population and recommend vaccination on a priority basis. Trials to assess the safety and efficacy of the COVID vaccines are underway and are likely to provide valuable insight into this matter.

摘要

自2020年初以来,新冠疫情在全球范围内造成了混乱。由于肝硬化固有的免疫功能障碍和总体健康状况不佳,慢性肝病(CLD)患者因新冠病毒感染而面临更高的死亡和发病风险。最近,一些针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的疫苗已在全球范围内获批紧急使用。尽管这些疫苗的2/3期试验表明它们在普通人群中是安全有效的,但CLD患者的数据却很稀少。参与这些试验的CLD患者数量较少,且尚未报告与肝脏相关的不良反应。各个肝脏学会已经针对这一人群制定了疫苗接种指南,并建议优先接种疫苗。评估新冠疫苗安全性和有效性的试验正在进行中,可能会为这一问题提供有价值的见解。

相似文献

1
COVID-19 Vaccines in Patients With Chronic Liver Disease.
J Clin Exp Hepatol. 2021 Nov-Dec;11(6):720-726. doi: 10.1016/j.jceh.2021.06.013. Epub 2021 Jun 19.
4
Risk factors and outcomes for acute-on-chronic liver failure in COVID-19: a large multi-center observational cohort study.
Hepatol Int. 2021 Jun;15(3):766-779. doi: 10.1007/s12072-021-10181-y. Epub 2021 Apr 7.
5
COVID-19 and the liver: What do we know so far?
World J Hepatol. 2021 May 27;13(5):522-532. doi: 10.4254/wjh.v13.i5.522.
6
Association between COVID-19 and chronic liver disease: Mechanism, diagnosis, damage, and treatment.
World J Virol. 2023 Jan 25;12(1):22-29. doi: 10.5501/wjv.v12.i1.22.
7
Chronic Liver Disease and Cirrhosis are Associated with Worse Outcomes Following SARS-CoV-2 Infection.
J Clin Exp Hepatol. 2023 Jul-Aug;13(4):592-600. doi: 10.1016/j.jceh.2023.01.014. Epub 2023 Feb 3.
9
COVID-19 vaccination and liver disease.
World J Gastroenterol. 2022 Dec 28;28(48):6791-6810. doi: 10.3748/wjg.v28.i48.6791.
10
Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update.
Front Med (Lausanne). 2022 Jun 22;9:924454. doi: 10.3389/fmed.2022.924454. eCollection 2022.

引用本文的文献

3
Impact of SARS-CoV-2 infection on liver disease.
Adv Lab Med. 2022 Jun 2;3(2):126-141. doi: 10.1515/almed-2022-0037. eCollection 2022 Jun.
5
Real-world effectiveness of COVID-19 vaccination in liver cirrhosis: a systematic review with meta-analysis of 51,834 patients.
Proc (Bayl Univ Med Cent). 2023 Jan 17;36(2):151-156. doi: 10.1080/08998280.2023.2165344. eCollection 2023.
6
COVID-19 and hepatic injury: cellular and molecular mechanisms in diverse liver cells.
World J Gastroenterol. 2023 Jan 21;29(3):425-449. doi: 10.3748/wjg.v29.i3.425.
7
COVID-19 and liver injury: An ongoing challenge.
World J Gastroenterol. 2023 Jan 14;29(2):257-271. doi: 10.3748/wjg.v29.i2.257.
8
COVID-19 Vaccination in Patients with Chronic Liver Disease.
Viruses. 2022 Dec 13;14(12):2778. doi: 10.3390/v14122778.
9
Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield) in Patients with Liver Cirrhosis.
Vaccines (Basel). 2022 Oct 30;10(11):1837. doi: 10.3390/vaccines10111837.
10
Adverse reactions to inactivated COVID-19 vaccination in patients with chronic liver disease: The effect of anxiety.
Hum Vaccin Immunother. 2022 Nov 30;18(6):2136435. doi: 10.1080/21645515.2022.2136435. Epub 2022 Oct 26.

本文引用的文献

2
COVID-19 and liver disease: mechanistic and clinical perspectives.
Nat Rev Gastroenterol Hepatol. 2021 May;18(5):348-364. doi: 10.1038/s41575-021-00426-4. Epub 2021 Mar 10.
5
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.
Lancet Infect Dis. 2021 May;21(5):637-646. doi: 10.1016/S1473-3099(20)30942-7. Epub 2021 Jan 21.
6
SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question.
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):156-158. doi: 10.1016/S2468-1253(21)00008-X. Epub 2021 Jan 11.
7
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
9
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
10
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.
J Hepatol. 2021 Mar;74(3):567-577. doi: 10.1016/j.jhep.2020.09.024. Epub 2020 Oct 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验